What is Leerink Partnrs’ Estimate for Geron FY2026 Earnings?

Geron Co. (NASDAQ:GERN) – Investment analysts at Leerink Partnrs raised their FY2026 earnings estimates for Geron in a research note issued to investors on Sunday, December 8th. Leerink Partnrs analyst F. Khurshid now expects that the biopharmaceutical company will post earnings per share of $0.36 for the year, up from their prior estimate of $0.33. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share.

Several other research firms have also weighed in on GERN. Barclays raised Geron to a “strong-buy” rating in a research report on Friday, November 29th. HC Wainwright reiterated a “buy” rating and issued a $9.00 price objective on shares of Geron in a research note on Tuesday. Leerink Partners started coverage on Geron in a research note on Monday, September 9th. They issued an “outperform” rating and a $7.00 target price on the stock. Finally, Scotiabank started coverage on Geron in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $6.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $7.15.

Geron Trading Down 1.5 %

Geron stock opened at $3.92 on Wednesday. The company has a 50 day moving average price of $4.08 and a 200 day moving average price of $4.34. The firm has a market capitalization of $2.37 billion, a price-to-earnings ratio of -12.25 and a beta of 0.51. Geron has a 52 week low of $1.64 and a 52 week high of $5.34. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89.

Geron (NASDAQ:GERN) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.05. The company had revenue of $28.27 million during the quarter, compared to analyst estimates of $18.97 million. Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The business’s quarterly revenue was up 17138.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.08) earnings per share.

Institutional Investors Weigh In On Geron

Institutional investors have recently added to or reduced their stakes in the stock. Darwin Global Management Ltd. bought a new position in shares of Geron during the second quarter valued at $106,185,000. Renaissance Technologies LLC bought a new position in shares of Geron in the second quarter valued at approximately $3,315,000. RTW Investments LP acquired a new position in Geron in the third quarter worth $200,268,000. Algert Global LLC acquired a new stake in shares of Geron in the second quarter valued at $539,000. Finally, Farallon Capital Management LLC lifted its position in Geron by 124.6% during the 2nd quarter. Farallon Capital Management LLC now owns 16,837,000 shares of the biopharmaceutical company’s stock worth $71,389,000 after buying an additional 9,342,000 shares in the last quarter. 73.71% of the stock is owned by institutional investors and hedge funds.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.